我们如何治疗ANCA相关的血管炎:关注维持疗法
Dario Roccatello1, Roberta Fenoglio1, Emanuele De Simone1
1University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnet and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, ASL Città di Torino and University of Torino, 10154 Turin, Italy.
利图西马布 (RTX) 推用于维持抗中性粒细胞体抗体相关血管炎 (AAV) 的缓解. 重新治疗的决定取决于患者特定的疾病爆发风险,指导最佳的AAV管理策略.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 内部医学 内部医学
背景情况:
- 随着最近的进展,抗中性粒细胞质抗体相关血管炎 (AAV) 的结果有所改善.
- 利图西马布 (RTX) 现在是维持AAV缓解的首选治疗方法,包括多炎和微观多炎的粒状瘤.
- 目前的指导方针建议RTX用于AAV缓解维护.
研究的目的:
- 审查目前关于AAV的RTX维持疗法的证据.
- 讨论影响AAV患者RTX再治疗决定的因素.
- 为了突出AAV维持疗法的未满足需求.
主要方法:
- 对AAV维持疗法的临床试验的文献综述.
- 对AAV爆发患者风险因素的分析.
- 回顾意大利都灵G.Bosco中心医院的临床经验.
主要成果:
- 利图西马布 (RTX) 已在维持AAV患者的缓解方面表现出有效性.
- 个人风险评估对于确定RTX再处理时间表至关重要.
- 疾病爆发及其后果是AAV管理中的关键考虑因素.
结论:
- 利图西马布 (RTX) 是AAV缓解维护的基石.
- 个性化的再治疗策略对于优化患者的治疗结果至关重要.
- 需要进一步的研究来解决AAV治疗的剩余挑战.
更多相关视频
10:09Drug Treatment by Central Venous Catheter in a Mouse Model of Angiotensin II Induced Abdominal Aortic Aneurysm and Monitoring by 3D Ultrasound
Published on: August 4, 2022
04:49Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
Published on: May 16, 2025
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Ulcerative Colitis in IBD
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
